Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma
Frontiers in Oncology · 08.05.2026 · 16
DOI: 10.3389/fonc.2026.1738719 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 08.05.2026. Verfasst von Weiguang Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, the People's Hospital of Baoan Shenzhen, Shenzhen, Guangdong, China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The monocyte-to-lymphocyte ratio(MLR) as an immune indicator has been found to be associated with the prognosis of various tumors. This study aimed to determine prognostic value of MLR in patients with hepatocellular carcinoma (HCC) by the meta-analysis.
Methods
A comprehensive literature search was conducted in PubMed, Web of Science, and Embase up to July 25, 2025. Survival outcome included overall survival (OS), recurrence free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS) were analyzed.
Results
A total of 17 studies comprising 7113 patients were included in the meta-analysis. The pooled results displayed that high MLR was significantly associated with poor OS (HR:1.57,95% CI:1.22-2.02), RFS(HR:2.40,95%CI:1.73-3.33) and PFS(HR:2.04,95%CI:1.57-2.65).However, high MLR was not associated with DFS(HR:1.01,95%CI:0.86-1.18). The prognostic relevance of MLR in HCC was consistently demonstrated across subgroup analyses.
Conclusion
High MLR was associated with poor prognosis in patients with HCC. MLR may be a valuable and non-invasive prognostic indicator for HCC patients in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, the People's Hospital of Baoan Shenzhen, Shenzhen, Guangdong, China.
Zitieren
APA
Zhou, W., Xiong, L., Li, Z., Zhang, Z., Yang, J., & Cao, H. (2026). Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1738719
Vancouver
Zhou W, Xiong L, Li Z, Zhang Z, Yang J, Cao H. Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1738719
BibTeX
@article{Zhou2026,
author = {Zhou, Weiguang and Xiong, Longhui and Li, Zhijian and Zhang, Zhanqiao and Yang, Jianyang and Cao, Huan},
title = {Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1738719}
}
EUVIMED